公开(公告)号：US20040091461A1

公开(公告)日：2004-05-13

申请号：US10631168

申请日：2003-07-31

发明人： Bradley Kropp ,  Earl Y. Cheng ,  Yuan Yuan Zhang ,  H.K. Lin ,  Rick Cowan

IPC分类号： A61K045/00

CPC分类号： A61F2/02 ,  A61K35/12 ,  C12N5/0685 ,  C12N5/0697 ,  C12N2502/02 ,  C12N2502/1347 ,  C12N2502/1358 ,  C12N2502/253 ,  C12N2506/02 ,  C12N2506/1353 ,  C12N2533/92

摘要： A method for providing a urinary tract tissue graft composition includes providing a segment of small intestinal submucosa and positioning the segment of small intestinal submucosa in a tissue culture frame such that the segment of small intestinal submucosa is suspended and held in a taut position by the tissue culture frame. At least one multipotent cell type is isolated from a tissue specimen of a subject and cultured, and then seeded upon a surface of the segment of small intestinal submucosa, thereby forming a urinary tract tissue graft. Methods for repairing a damaged urinary tract tissue of a subject are also disclosed.

摘要翻译： 用于提供尿道组织移植组合物的方法包括提供一小段粘膜下层，并将小肠粘膜下层的部分定位在组织培养框架中，使得小肠粘膜下层的部分被组织悬挂并保持在紧张的位置 文化框架。 将至少一种多能细胞类型从受试者的组织标本中分离并培养，然后接种在小肠粘膜下层的表面上，由此形成尿道组织移植物。 还公开了修复受试者的受损尿路组织的方法。

公开(公告)号：US20030203484A1

公开(公告)日：2003-10-30

申请号：US10213526

申请日：2002-08-06

申请人： Philadelphia Health And Education Corporation ,  University of Medicine and Dentistry of New Jersey

发明人： Ira B. Black ,  Dale L. Woodbury ,  Darwin J. Prockop ,  Emily Schwarz

IPC分类号： C12N005/08 ,  A61K038/18 ,  A61K031/375 ,  A61K031/198 ,  A61K031/19 ,  A61K031/045 ,  A61K031/10

CPC分类号： C12N15/85 ,  A61K31/045 ,  A61K31/10 ,  A61K31/19 ,  A61K31/198 ,  A61K31/375 ,  A61K35/12 ,  A61K48/00 ,  C12N5/0619 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/815 ,  C12N2501/999 ,  C12N2506/1353

摘要： The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system.

摘要翻译： 本发明涉及通过使骨髓基质细胞与神经元分化诱导化合物接触来诱导哺乳动物骨髓基质细胞分化为神经细胞的方法。 本发明的神经元分化诱导化合物包括抗氧化剂，例如但不限于β-巯基乙醇，二甲基亚砜，丁基化羟基苯甲醚，丁基化羟基甲苯，抗坏血酸，富马酸二甲酯和正乙酰半胱氨酸。 一旦诱导分化为神经元细胞，细胞可用于细胞治疗，基因治疗或两者，用于治疗中枢神经系统的疾病，病症或病症。

公开(公告)号：US20030139410A1

公开(公告)日：2003-07-24

申请号：US10341683

申请日：2003-01-14

发明人： Kiminobu Sugaya ,  Tingyu Qu

IPC分类号： A61K031/541 ,  A61K031/5377 ,  A61K031/519

CPC分类号： A61K31/519 ,  A61K31/505 ,  A61K31/7088 ,  A61K35/12 ,  C12N5/0621 ,  C12N5/0623 ,  C12N5/0662 ,  C12N2500/90 ,  C12N2500/99 ,  C12N2501/06 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/165 ,  C12N2501/91 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2502/08 ,  C12N2506/1353

摘要： This invention provides cells and methods for stimulating proliferation and migration of endogenous and exogenous mammalian stem cells in vivo and in vitro. The invention provides reagents and methods for efficiently proliferating mammalian stem cells in an animal in need thereof and producing stem cells that can be re-introduced into an animal in need thereof to alleviate neurological and corporal disorders.

摘要翻译： 本发明提供用于在体内和体外刺激内源和外源哺乳动物干细胞的增殖和迁移的细胞和方法。 本发明提供用于在有需要的动物中有效增殖哺乳动物干细胞的试剂和方法，并且产生可以重新引入有需要的动物的干细胞以减轻神经系统和体内疾病。

公开(公告)号：US20020037278A1

公开(公告)日：2002-03-28

申请号：US09915853

申请日：2001-07-26

发明人： Takafumi Ueno ,  Toyoaki Murohara ,  Keith Allen Robinson ,  Nicolas A.F. Chronos ,  Sam Baldwin ,  Maria Palasis

IPC分类号： A61K045/00 ,  C12N005/08

CPC分类号： A61K35/28 ,  A61K48/00 ,  A61K2035/124 ,  C12N5/0663 ,  C12N5/0692 ,  C12N2500/84 ,  C12N2501/58 ,  C12N2501/91 ,  C12N2506/1353

摘要： This invention provides methods of forming new blood vessels in diseased or damaged tissue in a subject, methods of increasing blood flow to diseased or damaged tissue in a subject, and methods of increasing angiogenesis in diseased tissue in a subject, which methods comprise: a) isolating autologous bone marrow-mononuclear cells from the subject; and b) transplanting locally into the diseased or damaged tissue an effective amount of the autologous bone-marrow mononuclear cells, thereby forming new blood vessels in the diseased or damaged tissue. The new blood vessels may be capillaries or collateral vessels in ischemic tissue or any site of angiogenesis. Also provided are methods of treating tissue in disease or injury by local transplantation with an effective amount of the autologous bone marrow-mononuclear cells so as to induce vascularization in such diseased tissue.

摘要翻译： 本发明提供了在受试者的患病或受损组织中形成新血管的方法，增加受试者中患病或受损组织的血流量的方法，以及增加受试者患病组织中血管生成的方法，所述方法包括：a） 从受试者中分离自体骨髓单核细胞; 和b）将有效量的自体骨髓单核细胞局部移植到患病或受损组织中，从而在患病或受损组织中形成新的血管。 新血管可能是缺血组织中的毛细血管或侧支血管或任何血管发生部位。 还提供了通过局部移植用有效量的自体骨髓单核细胞治疗疾病或损伤组织以便在这种患病组织中诱导血管形成的方法。

公开(公告)号：US12109327B2

公开(公告)日：2024-10-08

申请号：US17401542

申请日：2021-08-13

申请人： KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY

发明人： Charlotte A. E. Hauser ,  Salwa Alshehri ,  Hepi H. Susapto

IPC分类号： A61L27/36 ,  A61L27/22 ,  B33Y10/00 ,  B33Y70/00 ,  B33Y80/00 ,  C12N5/077

CPC分类号： A61L27/365 ,  A61L27/22 ,  B33Y10/00 ,  B33Y70/00 ,  B33Y80/00 ,  C12N5/0654 ,  A61L2430/02 ,  C12N2506/1353 ,  C12N2513/00 ,  C12N2533/50

摘要： The present disclosure relates generally to an osteo-tissue graft capable of promoting bone tissue growth and regeneration, comprising at least one self-assemble peptide and mesenchymal stem cells (MSCs) in accordance with the present invention and a method of preparing such an osteo-tissue graft. The grafts are suitable for treatment of bone disorder or damages through tissue engineering, cellular replacement therapies as well as other applications.

公开(公告)号：US11976300B2

公开(公告)日：2024-05-07

申请号：US17046383

申请日：2019-04-11

申请人： Institute of Basic Medical Sciences Chinese Academy of Medical Sciences

发明人： Haiyan Xu ,  Jian Liu ,  Tao Wang ,  Bing Han ,  Jie Meng ,  Tao Wen

IPC分类号： C12N5/078 ,  A61K9/14 ,  A61K33/36 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P35/02

CPC分类号： C12N5/0641 ,  A61K9/146 ,  A61K33/36 ,  A61P7/00 ,  A61P7/02 ,  A61P7/06 ,  A61P35/02 ,  C12N2501/999 ,  C12N2506/1353

摘要： Disclosed is the use of a water-soluble realgar solid dispersion in the preparation of an erythroid differentiation inducer for bone marrow hematopoietic stem cells and/or bone marrow hematopoietic progenitor cells. The water-soluble realgar solid dispersion is prepared from raw materials comprising 1 part by weight of realgar, 1-20 parts by weight of a polymer, and 0-5 parts by weight of a surfactant. The water-soluble realgar solid dispersion can induce bone marrow hematopoietic stem and/or progenitor cells to be differentiated into red blood cells, promote the accumulation of red blood cells in bone marrow cells, effectively alleviate the decrease in the number of red blood cells caused by the suppression of the erythroid differentiation of bone marrow hematopoietic stem and/or progenitor cells, improve anemia caused by hematopoietic failure, and protect bone marrow cells from the killing effect.

公开(公告)号：US20190233885A1

公开(公告)日：2019-08-01

申请号：US16380846

申请日：2019-04-10

申请人： The Children's Medical Center Corporation ,  The United States of America, As Represented by the Secretary, Department of Health & Human Serviv

发明人： Anjana Rao ,  Mamta Tahiliani ,  Kian Peng Koh ,  Suneet Agarwal ,  Aravind Iyer

IPC分类号： C12Q1/6827 ,  G01N33/50 ,  G01N33/574 ,  C12N5/00 ,  C12N9/02 ,  G01N33/53 ,  C12Q1/6806 ,  C12N5/0783 ,  C12Q1/6869 ,  C12N15/873 ,  C12N5/074 ,  C12Q1/6886 ,  C12Q1/26

CPC分类号： C12Q1/6827 ,  C12N5/0018 ,  C12N5/0607 ,  C12N5/0637 ,  C12N5/0696 ,  C12N9/0071 ,  C12N15/873 ,  C12N2501/15 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2501/70 ,  C12N2501/71 ,  C12N2501/999 ,  C12N2506/1307 ,  C12N2506/1353 ,  C12N2510/00 ,  C12Q1/26 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6886 ,  C12Q2521/531 ,  C12Q2522/10 ,  C12Q2537/164 ,  C12Q2600/154 ,  G01N33/5011 ,  G01N33/5308 ,  G01N33/57426 ,  G01N33/57484 ,  G01N33/57496 ,  G01N2500/00

摘要： The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

公开(公告)号：US10052412B2

公开(公告)日：2018-08-21

申请号：US15235466

申请日：2016-08-12

申请人： New Jersey Institute of Technology

发明人： Treena L. Arinzeh ,  Norbert Weber ,  Michael Jaffe

IPC分类号： C12N5/00 ,  A61L27/38 ,  A61L27/16 ,  C12N5/0793

CPC分类号： A61L27/3895 ,  A61L27/16 ,  A61L27/383 ,  A61L27/3834 ,  A61L2400/12 ,  C12N5/0068 ,  C12N5/0619 ,  C12N2501/13 ,  C12N2506/1307 ,  C12N2506/1353 ,  C12N2533/30 ,  C08L27/16

摘要： Due to the size and complexity of tissues such as the spinal cord and articular cartilage, specialized constructs incorporating cells as well as smart materials may be a promising strategy for achieving functional recovery. Aspects of the present invention describe the use of an electroactive, or piezoelectric, material that will act as a scaffold for stem cell induced tissue repair. Embodiments of the inventive material can also act alone as an electroactive scaffold for repairing tissues. The piezoelectric material of the present invention acts as a highly sensitive mechanoelectrical transducer that will generate charges in response to minute vibrational forces.

公开(公告)号：US20180193386A1

公开(公告)日：2018-07-12

申请号：US15741204

申请日：2016-07-01

申请人： Beihao Stem Cell and Regenerative Medicine Research Institutes Co., Ltd. ,  Peking University

发明人： Hongkui DENG ,  Xiang LI ,  Xiaohan ZUO

IPC分类号： A61K35/30 ,  C12N5/074 ,  C12N5/0793

CPC分类号： A61K35/30 ,  A61K9/0019 ,  C12N5/0607 ,  C12N5/0619 ,  C12N2501/01 ,  C12N2501/115 ,  C12N2501/13 ,  C12N2501/15 ,  C12N2501/60 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2502/086 ,  C12N2503/02 ,  C12N2506/08 ,  C12N2506/1307 ,  C12N2506/1353 ,  C12N2506/1369 ,  C12N2506/1384 ,  C12N2506/1392

摘要： Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGFβ receptor inhibitors, and BET family bromodomain inhibitors and optionally, a selective inhibitor of ROCK or p38 MAPK. These cocktails are used in a method of inducing neuron-like properties in partially or completely differentiated non-neuronal cells. The method includes contacting cells of a first type (non-neuronal) with the CINPs for a sufficient period of time to result in reprogramming the cell into cells of a second type having neuron-like characteristics (CiNs). Isolated chemically induced neurons (CiNs) can be used in a number of applications, including but not limited to cell therapy.

公开(公告)号：US09969980B2

公开(公告)日：2018-05-15

申请号：US09960244

申请日：2001-09-21

申请人： Tony W. Ho ,  Gene C. Kopen ,  William F. Righter ,  J. Lynn Rutkowski ,  Joseph Wagner

发明人： Tony W. Ho ,  Gene C. Kopen ,  William F. Righter ,  J. Lynn Rutkowski ,  Joseph Wagner

IPC分类号： C12N5/00 ,  C12N5/077 ,  C12N5/0797 ,  C12N5/0775 ,  A61K35/12

CPC分类号： C12N5/0669 ,  A61K2035/124 ,  C12N5/0623 ,  C12N5/0663 ,  C12N2500/02 ,  C12N2500/32 ,  C12N2506/1353

摘要： Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.